Studies have found that JAKs inhibitors can inhibit the IFN signaling in human DCs, reduce CD80/CD86 expression and T cell stimulation ability (133), and reduce the production of various inflammatory cytokines including IFN-γ (134) in SLE mice. This evidence concerns the gene IFNG and systemic lupus erythematosus.